COVID-19 Treatment Using Methylene Blue and Photodynamic Therapy

SARS-CoV-2 Clinical Trial

Official title:

The Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04933864
• Other study ID #: 2206
• Status: Completed
• Phase: Phase 1
• Start date: April 24, 2020
• Est. completion date: July 30, 2020

Study information

• Verified date: June 2021
• Source: I.M. Sechenov First Moscow State Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

According to the epidemiological situation worldwide and the number of vaccinations made, there is little success in the fight against COVID-19. For many reasons, methylene blue is a promising drug for an active treatment against SARS-CoV-2 infected patients. Since methylene blue can work as a photosensitizer, photodynamic therapy as an antiviral treatment has great potential in the treatment of COVID-19. This clinical study investigated the effectiveness of SARS-CoV-2 infected people treatment using methylene blue and the following photodynamic therapy on the base of the L.L. Levshin Institute of Cluster Oncology (Department of Infectious Diseases №13) of I.M. Sechenov First Moscow State Medical University.

Description:

This is a randomized, parallel, single masking clinical study 60 participants aged 18-90 with one positive COVID-19 quantitative Polymerase Chain Reaction test and any severity of pneumonia (checked by computer tomography scans) were recruited. The experimental and control samples included 30 participants. Randomization was performed using the Random Number Table generated in STATISTICA Advanced 13.3. The physiological parameters including oxygen saturation, severity of pneumonia using computer tomography scans, heart rate, symptoms, and physical examination were collected. Participants in the experimental sample received methylthioninium chloride, Methylene Blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) orally in concentration 1 mg/kg in addition to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any. After 3 hours, photodynamic therapy of the participant's chest by a 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm^2 energy dose was performed for 50 minutes. If the participant is in a critical state, inhalation by 0.2 mg Methylene Blue 10 ml water solution and following photodynamic therapy of pharynx and nasal cavity using 650 nm laser source with 36 J/cm^2 energy dose during 10 minutes were performed. Participants in the control sample received only standard medical supportive therapy (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.). All next steps were performed for p participants from the experimental sample: 12 and 24 hours after photodynamic therapy, blood saturation were measured. 2 days after - participants will take a quantitative polymerase chain reaction test. 14 days after - computer tomography Aquilion One 640 (Canon Medical Systems Corporation, Registration Certificate FSZ 2008/01304, 02.07.2018) scans were performed. The participant's status scale (EQ-5D-3L, SHOCS-COVID score, validated) was checked on day 84. On 24 and 84 days all participants were checked whether they are alive or not by phone call. For participants in the control sample continuous check of blood saturation, quantitative Polymerase Chain Reaction tests after 2 and 14 days of treatment, and computer tomography scans were performed. The primary outcome of this study is to calculate the percentage of participants with negative quantitative Polymerase Chain Reaction test on SARS-CoV-2 by 2 days after methylene blue administration and photodynamic therapy. Experimental and control samples were comparable in gender, age, and severity of the disease. Z-test was used to analyze results on quantitative Polymerase Chain Reaction tests within control and experimental samples. For each sample paired Student t-test was used to analyze individual saturation changes. Wilcoxon criterion was used for data on severity of pneumonia and status scale.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 60
• Est. completion date: July 30, 2020
• Est. primary completion date: May 20, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

• signed informed consent
• age: 18-90 years
• positive quantitative Polymerase Chain Reaction test on SARS-CoV-2 infection
• negative pregnancy test in women
• any severity of pneumonia (computer tomography scans)

Non-inclusion Criteria:

• documented refusal to participate in the study
• treatment with a serotonergic drug
• connection to artificial lung ventilation with or without sedation
• history of G-6-Phosphatase deficiency
• pregnancy and breastfeeding
• medical records of cirrhosis
• active chronic hepatitis

Exclusion Criteria:

• myocardial infarction, developed after the patient was included in the study, but before the intervention
• bleeding, developed after the patient was included in the study, but before the intervention
• connection to artificial lung ventilation developed after the patient was included in the study, but before the intervention

Related Conditions & MeSH terms

• SARS-CoV-2

Intervention

Drug:
• Methylene Blue and Photodynamic Therapy
Treatment group. Methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 1 mg/kg concentration orally one time were added to the current therapy of the participant (e.g., azithromycin, hydroxychloroquine, aminodihydrophthalazinedione sodium, levofloxacin, etc.), if any, and irradiation of the participant's chest was performed by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 18 J/cm^2 energy dose. For critically ill participants: Inhalation by 0.2 mg methylene blue (SamaraMedProm, Russia, Registration number: MP-001834, 13.09.2012) 10 ml water solution and irradiation of pharynx and nasal cavity by 650 nm laser source (UFPh-675-01-BIOSPEC, BIOSPEC, Russia, Registration number: 2009/04648, 26.03.2009) with 36 J/cm^2 energy dose were performed.

Locations

Country	Name	City	State
Russian Federation	I.M. Sechenov First Moscow State Medical University (Sechenov University)	Moscow

Sponsors (2)

Lead Sponsor	Collaborator
I.M. Sechenov First Moscow State Medical University	Prokhorov General Physics Institute of the Russian Academy of Sciences (GPI RAS)

Country where clinical trial is conducted

Russian Federation, 

References & Publications (1)

Strakhovskaya, M. G., Meerovich, G. A., Kuskov, A. N., Gonchukov, S. A., & Loschenov, V. B. (2020, September 1). Photoinactivation of coronaviruses: Going along the optical spectrum. Laser Physics Letters. IOP Publishing Ltd. https://doi.org/10.1088/1612-202X/abab14

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The percentage of participants with negative quantitative Polymerase Chain Reaction test on SARS-CoV-2 on day 2 after methylene blue administration and photodynamic therapy	The percentage of participants with negative quantitative Polymerase Chain Reaction test was reported. Quantitative Polymerase Chain Reaction test was performed not earlier than 3-4 hours after the last meal, excluding the use of medicines for topical application (drops, sprays, etc.) before taking the test.	Day 2
Secondary	Comparison of oxygen saturation dynamics measured by pulse oximeter before and after treatment	The saturation dynamics after photodynamic therapy in 12 and 24 hours were reported	12 and 24 hours after photodynamic therapy
Secondary	The percentage of participants with positive dynamics in severity of pneumonia (e.g., from CT-4 to CT-2)	The percentage of participants that have a positive trend in severity of pneumonia (computer tomography scans) after treatment (e.g., from CT-4 to CT-2) was reported	Day 14
Secondary	The percentage of participants having positive dynamics in patient status scale (EQ-5D-3L, SHOCS-COVID score) after treatment	The percentage of participants that have positive dynamics in patient status scale (EQ-5D-3L, SHOCS-COVID score) was calculated	Day 84
Secondary	The percentage of participants alive at day 28	The percentage of participants still alive at day 28 of samples collection was reported	Day 28
Secondary	The percentage of participants alive at day 84	The percentage of participants still alive at day 84 of samples collection was reported	Day 84